Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial

Published on Apr 1, 1999in The Journal of Urology7.45
· DOI :10.1016/S0022-5347(01)61702-6
Sources
Abstract
đź“– Papers frequently viewed together
References0
Newest
Cited By15
Newest
#1Aung Zaw Zaw Phyo (Monash University)H-Index: 3
#2Rosanne Freak-Poli (Monash University)H-Index: 18
Last. Joanne Ryan (Monash University)H-Index: 35
view all 7 authors...
Quality of life (QoL) is multi-dimensional concept of an individual’ general well-being status in relation to their value, environment, cultural and social context in which they live. This study aimed to quantitatively synthesise available evidence on the association between QoL and mortality in the general population. An electronic search was conducted using three bibliographic databases, MEDLINE, EMBASE and PsycINFO. Inclusion criteria were studies that assessed QoL using standardized tools an...
Source
#1Thomas M. Atkinson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 24
#2Angela M. Stover (UNC: University of North Carolina at Chapel Hill)H-Index: 20
Last. Ethan Basch (UNC: University of North Carolina at Chapel Hill)H-Index: 82
view all 9 authors...
: Patient-reported outcomes (PROs) are increasingly used to monitor treatment-related symptoms and physical function decrements in cancer clinical trials. As more patients enter survivorship, it is important to capture PRO physical function throughout trials to help restore pretreatment levels of function. We completed a systematic review of PRO physical function measures used in cancer clinical trials and evaluated their psychometric properties on the basis of guidelines from the US Food and Dr...
Source
Background Owing to a scarcity of data or other causes, patient research on the orphan population is lacking in most societies. Consequently, the primary goal of this study was to explore quality of life (QOL) and quality of care (QOC) among orphan patients (OPs) receiving tertiary healthcare services in Saudi Arabia (SA).
Source
#1Maha Hussain (UM: University of Michigan)H-Index: 80
#2Catherine M. TangenH-Index: 16
Last. Ian M. Thompson (University of Texas Health Science Center at San Antonio)H-Index: 114
view all 21 authors...
Background Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence. Methods Men with newly diagnosed, metastatic, hormone-sensitive prostate cancer, a performance status of 0 to 2, and a prostate-specific antigen (PSA) level of 5 ng per milliliter or higher received a luteinizing hormone–releasing hormone anal...
Source
#1Katherine R. Sterba (MUSC: Medical University of South Carolina)H-Index: 17
#2Richard J. Swartz (University of Texas MD Anderson Cancer Center)H-Index: 10
Last. Curtis A. Pettaway (University of Texas MD Anderson Cancer Center)H-Index: 69
view all 5 authors...
Purpose We examined quality of life in spouses of men in the Post-Adjuvant Androgen Deprivation trial after radical prostatectomy.
Source
#1Abhay R. Shelke (UR: University of Rochester)H-Index: 6
#2Supriya G. Mohile (UR: University of Rochester)H-Index: 62
Prostate Cancer (PCa) is the second most common cancer in United States and remains the second leading cause of death in the Western world. Because the median age of diagnosis for men with prostate cancer is greater than 75 years, PCa can be considered a disease of the elderly. Several disease-specific factors (e.g., stage, tumor grade, prostate-specific antigen (PSA) level) and patient-specific factors (e.g., age, co-morbidity, and functional status) need to be considered in the decision-making...
Source
#1Supriya G. Mohile (UR: University of Rochester)H-Index: 62
#2Karen M. Mustian (UR: University of Rochester)H-Index: 58
Last. William Dale (U of C: University of Chicago)H-Index: 43
view all 5 authors...
Prostate cancer is the most common malignancy in older men. With the aging of the population, the number of older men with prostate cancer will grow rapidly. Androgen deprivation therapy (ADT) is the mainstay of treatment for men with systemic disease and is increasingly utilized as primary therapy or in combination with other therapies for localized disease. Side effects of therapy are multifold and include hot flashes, osteoporosis, and adverse psychological and metabolic effects. Recent resea...
Source
#1Himu Lukka (Juravinski Cancer Centre)H-Index: 30
#2Tricia Waldron (Cancer Care Ontario)H-Index: 8
Last. John TrachtenbergH-Index: 72
view all 5 authors...
Introduction Maximal androgen blockade (mab) versus castration alone in patients with metastatic prostate cancer has been extensively evaluated in randomized trials. The inconsistent results have led to the publication of multiple meta-analyses. The present review examines the evidence from meta-analytic reports to determine whether mab using agents such as flutamide, nilutamide, and cyproterone acetate (cpa) is associated with a survival advantage.
Source
Androgen deprivation therapy (ADT) is indicated for the treatment of metastatic prostate cancer and locally advanced disease. In addition to sexual side effects, long-term ADT results in several other changes, including hot flashes; gynecomastia; changes in body composition, metabolism, and the cardiovascular system; osteoporosis; anemia; psychiatric and cognitive problems; and fatigue and diminished quality of life. This review discusses these complications of ADT and treatments aimed at reduci...
Source
Hormonal therapy has been the standard of care for advanced prostate cancer for over 6 decades. Treatments to suppress testosterone have expanded beyond surgical castration and estrogens to include steroidal and nonsteroidal antiandrogens, luteinizing hormone-releasing hormone agonists, and, most recently, gonadotropin-releasing hormone antagonists. Yet, despite this extensive therapeutic armamentarium, long-term survival of patients with advanced prostate cancer remains poor. Many issues regard...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.